top of page
  • Writer's picturePraetego

Praetego’s PTG-630 Successfully Completes a Pre-IND Meeting with the FDA’s Division of Neurology

Praetego successfully completed a Pre-IND meeting with the FDA’s Division of Neurology for PTG-630 to limit early Alzheimer’s disease. The FDA review team agreed to the IND-enabling plan as proposed, thus confirming the suitability of PTG-630’s pathway to clinical readiness. Praetego is excited to initiate the necessary studies to prepare for an IND and be in clinic in 2025. PTG-630 has the potential to be an ideal drug candidate to protect patients from disease progression in Alzheimer’s disease.

Comments


bottom of page